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Introduction
The Juvenile Arthritis Disease Activity Score (JADAS) [1]
is becoming widely accepted in juvenile idiopathic arthri-
tis (JIA) for defining a treat to target strategy.
Objectives
To evaluate patients (pts) treated with adalimumab
(ADA) (±methotrexate [MTX]) that achieved minimal
disease activity (MDA) and both MDA and normalization
of function.
Methods
This post hoc analysis assessed pts aged 4-17 with polyar-
ticular JIA enrolled in a phase 3 clinical trial (DE038)[2],
which consisted of a 16 week (wk) open-label (OL) lead-
in with ADA±MTX, 32wk double-blind (DB) phase with
ADA or placebo (PBO)±MTX, and OL extension (OLE)
with ADA±MTX up to 346wks. Outcomes were assessed
by 27-joint JADAS (JADAS27), based on C-reactive pro-
tein, and Childhood Health Assessment Questionnaire
Disability Index (CHAQ-DI). MDA was defined as
JADAS27<3.8 and normal function as CHAQ-DI<0.5. Pts
who entered the DB phase were included; data were stra-
tified by MTX treatment (tx) at entry.
Results
At baseline, 75 pts on MTX had a mean JADAS27 of 21.2
and CHAQ-DI of 0.9, and 58 pts who were MTX naïve
or had withdrawn from MTX had a mean JADAS27 of
23.8 and CHAQ-DI of 1.2. After 16wks of OL ADA, the
mean JADAS27 was 6.1 and 6.7 and CHAQ-DI was 0.4
and 0.5 for ADA+MTX and ADA-MTX, respectively.
Clinical improvements were seen at wk48 and wk88, and
the mean JADAS27 at wk88 was 2.6, 3.0, 4.3, and 5.0 for
ADA+MTX, ADA-MTX, PBO+MTX, and PBO-MTX,
respectively. No pts had MDA or normal function at
baseline; however, a good proportion achieved MDA and
normal function during OL ADA. Fewer pts achieved
MDA and normal function in the PBO tx compared with
ADA continuation at both wk48 and wk88. Table 1.
P-value based on Cochran-Mantel-Haenszel statistics
to test if there was a difference between ADA continua-
tion vs. PBO.
Conclusion
ADA±MTX resulted in a high percentage of pts achieving/
sustaining MDA and normal function. Some improvement
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Table 1
n (%) Minimal Disease Activity
ADA Continuation PBO P-value
+MTX -MTX +MTX -MTX
Week 16 28 (37.3) 19 (33.9) NA NA NA
Week 48 19 (76.0) 14 (56.6) 15 (62.5) 13 (68.4) 0.8919
Week 88 26 (83.9) 20 (76.9) 14 (50.0) 13 (65.0) 0.0075
Minimal Disease Activity with Normal Function
Week 16 21 (28.0) 15 (26.8) NA NA NA
Week 48 17 (68.0) 12 (48.0) 15 (62.5) 13 (68.4) 0.5155
Week 88 24 (77.4) 17 (65.4) 14 (50.0) 11 (55.0) 0.0362
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was seen with PBO during the DB period, but continued
ADA tx shows better overall outcomes. A target of com-
prehensive disease control with MDA and normal func-
tion is achievable and aligned with current goals of JIA tx.
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